For the second day in a row, investors in Nabriva Therapeutics (NASDAQ: NBRV) are enjoying double-digit gains. Shares of the clinical-stage biotech are up 15% as of 11:30 a.m. EDT on Tuesday. The gains can be credited to the news that it is raising capital through a secondary common stock offering and from some bullish Wall Street commentary.